Detalhe da pesquisa
1.
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Hepatology
; 74(5): 2652-2669, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34157147
2.
DNA Methylation Profiling of Human Hepatocarcinogenesis.
Hepatology
; 74(1): 183-199, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33237575
3.
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
J Hepatol
; 75(4): 865-878, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33992698
4.
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
J Hepatol
; 73(2): 315-327, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32173382
5.
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Gastroenterology
; 157(5): 1383-1397.e11, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31344396
6.
Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials.
Br J Cancer
; 121(4): 340-343, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285588
7.
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Gut
; 66(3): 530-540, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26658144
8.
Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
J Hepatol
; 75(6): 1515, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34627652
9.
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Gastroenterology
; 144(4): 829-40, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23295441
10.
Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.
Mol Cancer Ther
; 22(4): 485-498, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780225
11.
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Clin Cancer Res
; 28(11): 2449-2460, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302601
12.
Gene expression in fixed tissues and outcome in hepatocellular carcinoma.
N Engl J Med
; 359(19): 1995-2004, 2008 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-18923165
13.
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
J Hepatol
; 52(4): 550-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20206398
14.
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
J Hepatol
; 51(4): 725-33, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19665249
15.
Pivotal role of mTOR signaling in hepatocellular carcinoma.
Gastroenterology
; 135(6): 1972-83, 1983.e1-11, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18929564
16.
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Cancer Res
; 68(16): 6779-88, 2008 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18701503